Wenhua B. Zheng

Sar, 999078, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 133 publications

Artemisinin Attenuates Aβ1-42 Aggregation via the CaMK IV/PKA-CREB-Ace-H4 Cascade in Neuronal Cultures and 3xTg-AD Models.

Artemisinin Attenuates Aβ1-42 Aggregation via the CaMK IV/PKA-CREB-Ace-H4 Cascade in Neuronal Cultures and 3xTg-AD Models.

Journal: The American journal of Chinese medicine

Published: August 20, 2026

Diagnostic value of nanopore-based targeted sequencing technology for subclinical tuberculosis.

Diagnostic value of nanopore-based targeted sequencing technology for subclinical tuberculosis.

Journal: BMC microbiology

Published: February 14, 2026

Canagliflozin Alleviates Pressure Overload-Induced Cardiac Dysfunction via PINK1 Regulation by Inhibiting Mitophagy-Driven Ferroptosis.

Canagliflozin Alleviates Pressure Overload-Induced Cardiac Dysfunction via PINK1 Regulation by Inhibiting Mitophagy-Driven Ferroptosis.

Journal: The Canadian journal of cardiology

Published: January 29, 2026

A spatiotemporally coordinated curcumin-based microneedle patch for SDF-1α delivery and synergistic myocardial infarction therapy.

A spatiotemporally coordinated curcumin-based microneedle patch for SDF-1α delivery and synergistic myocardial infarction therapy.

Journal: Journal of nanobiotechnology

Published: November 11, 2025

Identification of circulatory neuro-related proteins in Parkinson's disease: an integrated genetic-proteomic-clinical study.

Identification of circulatory neuro-related proteins in Parkinson's disease: an integrated genetic-proteomic-clinical study.

Journal: EBioMedicine

Published: September 25, 2025

Artemisinin exerts antidepressant-like effects via activation of AKT and ERK signaling pathways.

Artemisinin exerts antidepressant-like effects via activation of AKT and ERK signaling pathways.

Journal: Frontiers in pharmacology

Published: June 06, 2025

FoxO3a-Mediated Modulation of PD-L1 Expression and Inhibition by Dihydroartemisinin in Triple-Negative Breast Cancer.

FoxO3a-Mediated Modulation of PD-L1 Expression and Inhibition by Dihydroartemisinin in Triple-Negative Breast Cancer.

Journal: Journal of cellular and molecular medicine

Published: March 26, 2025

Artemether Improves Aβ1-42-Induced Mitochondrial Dysfunction and Protects Against Blood-Brain Barrier Damage Through Activating the CAMKK2/AMPK/PGC1α Signaling Pathway.

Artemether Improves Aβ1-42-Induced Mitochondrial Dysfunction and Protects Against Blood-Brain Barrier Damage Through Activating the CAMKK2/AMPK/PGC1α Signaling Pathway.

Journal: Molecular neurobiology

Published: March 13, 2025

Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis.

Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis.

Journal: eGastroenterology

Published: January 28, 2025

Artemisinin protected human bronchial epithelial cells from amiodarone-induced oxidative damage via 5'-AMP-activated protein kinase (AMPK) activation.

Artemisinin protected human bronchial epithelial cells from amiodarone-induced oxidative damage via 5'-AMP-activated protein kinase (AMPK) activation.

Journal: Redox report : communications in free radical research

Published: January 13, 2025

Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development.

Discovery and proof-of-concept study of a novel highly selective sigma-1 receptor agonist for antipsychotic drug development.

Journal: Acta pharmaceutica Sinica. B

Published: January 05, 2025

Development of asparagine endopeptidase inhibitors for treating neurodegenerative diseases.

Development of asparagine endopeptidase inhibitors for treating neurodegenerative diseases.

Journal: Trends in molecular medicine

Published: October 17, 2024

Showing 1-12 of 133

Last Updated: 09/26/2026